Clinical Trial Results: Positive clinical trial outcomes for IMVT-1402, Immunovant's lead drug candidate, typically drive the stock price up, while negative or inconclusive results can cause it to fall.

Regulatory Approvals: FDA approval for IMVT-1402 in any of its target indications (e.g., thyroid eye disease, warm autoimmune hemolytic anemia) would likely result in a significant increase in the stock price.

Competition: The success and progress of competing therapies targeting the same diseases as IMVT-1402 can influence investor sentiment and impact Immunovant's stock price.

Financial Performance: Immunovant's cash runway, spending rate, and ability to raise capital influence investor confidence. Positive financial news generally leads to stock appreciation.

Market Conditions: General market trends, including overall economic conditions and investor sentiment towards biotechnology stocks, can affect Immunovant's stock price.

Partnerships and Collaborations: Announcements of strategic partnerships or collaborations with other pharmaceutical companies can positively influence the stock price.

Management Changes: Significant changes in Immunovant's management team can impact investor perception and the stock's performance.

Analyst Ratings: Upgrades or downgrades from financial analysts can influence investor behavior and impact the stock price.

Data Readouts: Additional data from ongoing or completed clinical trials, even outside of formal trial results, can affect investor expectations and price.

Patent Protection: The strength and scope of Immunovant's patent portfolio for IMVT-1402 are crucial for long-term value and can impact investor confidence.